155 related articles for article (PubMed ID: 17360963)
1. The tumor-necrosis-factor-associated periodic syndrome, the brain, and tumor-necrosis-factor-alpha antagonists.
Wildemann B; Rudofsky G; Kress B; Jarius S; Konig F; Schwenger V
Neurology; 2007 May; 68(20):1742-4. PubMed ID: 17360963
[No Abstract] [Full Text] [Related]
2. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment.
Stojanov S; Dejaco C; Lohse P; Huss K; Duftner C; Belohradsky BH; Herold M; Schirmer M
Ann Rheum Dis; 2008 Sep; 67(9):1292-8. PubMed ID: 18180277
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor receptor-associated periodic syndrome as a cause of recurrent abdominal pain in identical twins and description of a novel mutation of the TNFRSF1A gene.
Lee RU; Saland S; Sullivan S
J Pediatr Gastroenterol Nutr; 2013 Apr; 56(4):e22-3. PubMed ID: 22343913
[No Abstract] [Full Text] [Related]
4. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome.
Quillinan N; Mannion G; Mohammad A; Coughlan R; Dickie LJ; McDermott MF; McGonagle D
Ann Rheum Dis; 2011 Sep; 70(9):1692-3. PubMed ID: 21378401
[No Abstract] [Full Text] [Related]
5. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.
Nowlan ML; Drewe E; Bulsara H; Esposito N; Robins RA; Tighe PJ; Powell RJ; Todd I
Rheumatology (Oxford); 2006 Jan; 45(1):31-7. PubMed ID: 16287931
[TBL] [Abstract][Full Text] [Related]
6. A new mutation causing autosomal dominant periodic fever syndrome in a Danish family.
Weyhreter H; Schwartz M; Kristensen TD; Valerius NH; Paerregaard A
J Pediatr; 2003 Feb; 142(2):191-3. PubMed ID: 12584543
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tumor necrosis factor alpha blockade for enthesitis in spondylarthropathy: comment on the article by Marzo-Ortega et al.
Olivieri I; Padula A; Scarano E
Arthritis Rheum; 2002 Dec; 46(12):3396-8; author reply 3398. PubMed ID: 12483753
[No Abstract] [Full Text] [Related]
8. Tumor necrosis factor receptor-associated periodic fever syndrome in a 58-year-old man: caution not to discount TRAPS as a diagnosis in older patients.
Sinožić D; Toplak N; Milotić I
J Clin Rheumatol; 2011 Sep; 17(6):325-8. PubMed ID: 21869706
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis.
Marzo-Ortega H; Emery P; McGonagle D
N Engl J Med; 2003 Jan; 348(4):359-61; author reply 359-61. PubMed ID: 12542065
[No Abstract] [Full Text] [Related]
10. Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected].
Cortis E; De Benedetti F; Insalaco A; Cioschi S; Muratori F; D'Urbano LE; Ugazio AG
J Pediatr; 2004 Dec; 145(6):851-5. PubMed ID: 15580218
[TBL] [Abstract][Full Text] [Related]
11. Recalcitrant lithium-induced psoriasis in a suicidal patient alleviated by tumour necrosis factor-alpha inhibition.
Wachter T; Murach WM; Bröcker EB; Schön MP
Br J Dermatol; 2007 Sep; 157(3):627-9. PubMed ID: 17596151
[No Abstract] [Full Text] [Related]
12. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C.
Niewold TB; Gibofsky A
Arthritis Rheum; 2006 Jul; 54(7):2335-7. PubMed ID: 16802375
[No Abstract] [Full Text] [Related]
13. TNFRSF1A R92Q mutation in association with a multiple sclerosis-like demyelinating syndrome.
Hoffmann LA; Lohse P; König FB; Feneberg W; Hohlfeld R; Kümpfel T
Neurology; 2008 Mar; 70(13 Pt 2):1155-6. PubMed ID: 18287568
[No Abstract] [Full Text] [Related]
14. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis.
Kallinich T; Briese S; Roesler J; Rudolph B; Sarioglu N; Blankenstein O; Keitzer R; Querfeld U; Haffner D
J Rheumatol; 2004 Dec; 31(12):2519-22. PubMed ID: 15570662
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of Langerhans'-cell histiocytosis with etanercept.
Henter JI; Karlén J; Calming U; Bernstrand C; Andersson U; Fadeel B
N Engl J Med; 2001 Nov; 345(21):1577-8. PubMed ID: 11794238
[No Abstract] [Full Text] [Related]
16. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.
Sweiss NJ; Curran J; Baughman RP
Clin Dermatol; 2007; 25(3):341-6. PubMed ID: 17560312
[TBL] [Abstract][Full Text] [Related]
17. Alopecia areata during etanercept therapy.
Pan Y; Rao NA
Ocul Immunol Inflamm; 2009; 17(2):127-9. PubMed ID: 19412875
[TBL] [Abstract][Full Text] [Related]
18. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy.
Sacré K; Brihaye B; Lidove O; Papo T; Pocidalo MA; Cuisset L; Dodé C
J Rheumatol; 2008 Feb; 35(2):357-8. PubMed ID: 18260167
[No Abstract] [Full Text] [Related]
19. Successful use of etanercept in type I pityriasis rubra pilaris.
Seckin D; Tula E; Ergun T
Br J Dermatol; 2008 Mar; 158(3):642-4. PubMed ID: 18081896
[No Abstract] [Full Text] [Related]
20. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) or familial Hibernian fever: presentation in a four-day-old infant.
Savage T; Loftus BG; Tormey V; McDermott MF; Moylett E
J Clin Rheumatol; 2008 Dec; 14(6):342-5. PubMed ID: 18690165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
